Clearance of serum hepatitis C virus RNA after interferon therapy in relation to virus genotype.

K Kanai, M Kako, T Aikawa, T Kumada, T Kawasaki, T Hatahara, Y Oka, M Mizokami, T Sakai, K Iwata
{"title":"Clearance of serum hepatitis C virus RNA after interferon therapy in relation to virus genotype.","authors":"K Kanai,&nbsp;M Kako,&nbsp;T Aikawa,&nbsp;T Kumada,&nbsp;T Kawasaki,&nbsp;T Hatahara,&nbsp;Y Oka,&nbsp;M Mizokami,&nbsp;T Sakai,&nbsp;K Iwata","doi":"10.1111/j.1600-0676.1995.tb00668.x","DOIUrl":null,"url":null,"abstract":"<p><p>The effect of recombinant interferon-alfa on serum HCV RNA levels in Japanese patients with chronic hepatitis C was investigated. At 24 weeks of treatment, 41 (32.5%) of 126 patients lost HCV RNA from serum, and aminotransferases were normalized in 31 (75.6%) of these 41 cases. HCV genotypes were categorized into four types (Type I, II, III, IV); the frequencies among the patients were: Type I: 0%, Type II: 70.6%, Type III: 20.6%, and Type IV: 6.3%. At the end of the 24-week treatment, HCV RNA levels were remarkably decreased in Type III patients and became undetectable in 18 (69.2%) of 26. In contrast, only 18 (20.2%) of 89 patients with Type II and two of eight with Type IV lost HCV RNA from sera. The relation between HCV genotype (Type III) and response to IFN therapy was also confirmed using a logistic regression model. HCV genotype seems to be an important factor in determining the response to IFN in patients with chronic hepatitis C.</p>","PeriodicalId":18183,"journal":{"name":"Liver","volume":"15 4","pages":"185-8"},"PeriodicalIF":0.0000,"publicationDate":"1995-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1600-0676.1995.tb00668.x","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/j.1600-0676.1995.tb00668.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14

Abstract

The effect of recombinant interferon-alfa on serum HCV RNA levels in Japanese patients with chronic hepatitis C was investigated. At 24 weeks of treatment, 41 (32.5%) of 126 patients lost HCV RNA from serum, and aminotransferases were normalized in 31 (75.6%) of these 41 cases. HCV genotypes were categorized into four types (Type I, II, III, IV); the frequencies among the patients were: Type I: 0%, Type II: 70.6%, Type III: 20.6%, and Type IV: 6.3%. At the end of the 24-week treatment, HCV RNA levels were remarkably decreased in Type III patients and became undetectable in 18 (69.2%) of 26. In contrast, only 18 (20.2%) of 89 patients with Type II and two of eight with Type IV lost HCV RNA from sera. The relation between HCV genotype (Type III) and response to IFN therapy was also confirmed using a logistic regression model. HCV genotype seems to be an important factor in determining the response to IFN in patients with chronic hepatitis C.

干扰素治疗后血清丙型肝炎病毒RNA清除率与病毒基因型的关系
研究了重组干扰素对日本慢性丙型肝炎患者血清HCV RNA水平的影响。在治疗24周时,126例患者中有41例(32.5%)患者血清中HCV RNA丢失,其中31例(75.6%)患者转氨酶恢复正常。HCV基因型分为ⅰ型、ⅱ型、ⅲ型、ⅳ型;其中,ⅰ型占0%,ⅱ型占70.6%,ⅲ型占20.6%,ⅳ型占6.3%。在24周治疗结束时,III型患者的HCV RNA水平显著降低,26例患者中有18例(69.2%)无法检测到HCV RNA。相比之下,89例II型患者中只有18例(20.2%)和8例IV型患者中的2例从血清中丢失HCV RNA。HCV基因型(III型)与IFN治疗反应之间的关系也通过logistic回归模型得到证实。HCV基因型似乎是决定慢性丙型肝炎患者对干扰素反应的一个重要因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信